Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (671-680 of 869) with videos related to

Pageof 87
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple MyelomaIrene M Ghobrial, Chia-Jen Liu, Robert A Redd, et al.
Cancer Research|November 2, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Molecular Cancer Research : MCR|November 3, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivoHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomibPaul G Richardson, Hannah Briemberg, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2018
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine WarheadsKrista Kinneer, John Meekin, Arnaud C Tiberghien, et al.
Blood Advances|June 11, 2024
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapiesShuhui Deng, Sanika Derebail, Vera Joy Weiler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialPaul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.
Leukemia|May 31, 2019
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signalingMatthew Ho, Tianzeng Chen, Jiye Liu, et al.
Pageof 87

Showing results (671-680 of 869) with videos related to

Sort By:
Pageof 87
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple MyelomaIrene M Ghobrial, Chia-Jen Liu, Robert A Redd, et al.
Cancer Research|November 2, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Molecular Cancer Research : MCR|November 3, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivoHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomibPaul G Richardson, Hannah Briemberg, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2018
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine WarheadsKrista Kinneer, John Meekin, Arnaud C Tiberghien, et al.
Blood Advances|June 11, 2024
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapiesShuhui Deng, Sanika Derebail, Vera Joy Weiler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialPaul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.
Leukemia|May 31, 2019
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signalingMatthew Ho, Tianzeng Chen, Jiye Liu, et al.
Pageof 87